A universal contrast agent platform for CT and MRI.
LSMedical is developing a safer dual-modality nanoparticle contrast agent — a single rapid-clearance platform offering an alternative for patients where current gadolinium and iodine-based agents are limited.
- Designed for safer imaging in vulnerable patient populations
- Compatible with existing CT and MRI infrastructure
- Built for earlier and more accurate diagnosis
Current contrast agents were never designed for today's clinical reality.
Modern imaging depends on contrast agents developed decades ago. While these agents remain clinically valuable, they present growing limitations in patient safety, supply resilience, and diagnostic accessibility. Hospitals and radiologists increasingly face a difficult compromise between image quality and patient risk.
Gadolinium retention and toxicity concerns
MRI contrast agents based on gadolinium have been associated with tissue deposition and increased concern in patients with impaired renal function.
Severe reactions to iodine-based CT agents
Iodinated CT contrast agents can trigger serious allergic and renal complications, limiting safe use in vulnerable populations.
Millions of patients remain underserved
Patients with chronic kidney disease, autoimmune conditions, and paediatric populations are frequently excluded from optimal contrast imaging pathways.
Diagnostic imaging should not require a trade-off between clarity and safety.
Designed for high-impact clinical applications.
The platform is initially focused on areas where safer contrast imaging could significantly improve patient access and diagnostic capability.
Multiple Sclerosis
Earlier lesion detection and safer repeat imaging.
Oncology
Enhanced tumour visibility and improved longitudinal monitoring.
Paediatric Imaging
Reduced exposure concerns for younger patient populations.
Chronic Kidney Disease
A potential safer imaging pathway for patients currently excluded from contrast procedures.
The imaging market is entering a transition period.
Regulatory pressure, rising chronic disease prevalence, and geopolitical supply instability are accelerating the need for next-generation contrast technologies.
Increasing scrutiny on long-term safety.
Global regulators continue to increase scrutiny around gadolinium retention and long-term safety, driving demand for safer next-generation alternatives.
The patient need is growing fast.
Over 850 million people worldwide are estimated to live with chronic kidney disease — the population most vulnerable to existing contrast limitations.
The supply chain is exposed.
Rare-earth supply concentration creates increasing strategic pressure across healthcare and advanced imaging markets, accelerating the search for supply-independent alternatives.
Demand for earlier diagnosis is expanding.
Demand for earlier and more precise imaging continues to expand across oncology, neurology, and chronic disease monitoring — widening the gap that current agents leave behind.
One platform. Two imaging modalities.
LSMedical has developed a proprietary nanoparticle platform engineered for both CT and MRI compatibility within a single injectable contrast agent. The platform is designed to improve safety, simplify imaging workflows, and enable broader patient access to high-quality diagnostic imaging.
Dual-modality functionality
Designed to operate across both MRI and CT imaging systems using one unified contrast platform.
Rapid clearance profile
Engineered for efficient clearance from the body to minimise long-term deposition concerns.
High contrast performance
Optimised for strong signal enhancement and early-stage diagnostic sensitivity.
Workflow compatibility
Designed for integration into existing hospital imaging infrastructure without requiring new equipment or protocol redesign.
More than a contrast agent — a platform architecture.
LSMedical's intellectual property strategy is designed for long-term scientific and commercial defensibility across nanoparticle composition, synthesis methodology, dual-modality imaging capability, rapid-clearance engineering, formulation development, and scalable manufacturing. Beyond formal patent protection, the platform benefits from years of accumulated synthesis and formulation expertise — creating multiple layers of technical and operational defensibility that are difficult to replicate through conventional contrast approaches.
LSMedical's goal is not simply to develop a new contrast agent, but to establish a differentiated imaging platform designed for long-term clinical relevance and strategic value creation.
Built from fundamental nanoparticle science.
Our platform combines advanced materials engineering, contrast chemistry, and biomedical imaging research to create highly controlled nanoparticle structures with tunable imaging properties.
The work spans five core scientific disciplines — each method developed, characterised, and validated in-house to translate from laboratory research to clinical-grade production.
- Proprietary synthesis methods
- Tunable particle architecture
- Engineered surface chemistry
- Dual-modality contrast physics
- GMP-grade scale-up methodology
A team combining deep scientific expertise with operational execution.
LSMedical is led by a founding team that combines two decades of contrast agent research with experience scaling deep-tech and medical-device businesses.
Liis Seinberg, PhD
Materials scientist with 20 years developing contrast agent synthesis methods — the scientific foundation of LSMedical's platform. PhD in materials science from Kyoto University. Previously founded and exited a medical device company, and scaled B2B medical-device sales at Abbott. Originator of the platform's core nanoparticle chemistry.
Gert Seinberg
Finance leader with 15 years as head of accounting across venture-backed startups. Held finance leadership roles at ZTA, Starship Technologies and Snyk (UK), and served as CFO of FlyAdvance Aviation Group (USA). Leads LSMedical's financial strategy, fundraising and grant management.
Heiti Kender
Deep-tech founder of 10+ companies with specialist expertise in magnetic nanoparticle synthesis — core to the LSMedical platform. Engineering background spanning LED systems, dialysis technology and complex real-time simulation. Leads nanoparticle development and manufacturing scale-up.
A network built to de-risk clinical translation.
LSMedical works alongside clinical leaders and imaging scientists across leading European and US institutions — supporting trial design, in vivo validation, and the path toward Phase I.
Advancing through preclinical validation.
LSMedical is progressing through preclinical development in collaboration with leading research institutions and scientific partners.
Published in vitro data
Foundational laboratory data supporting imaging functionality and nanoparticle behaviour.
Manufacturing validation
Scalable synthesis processes developed for reproducibility and future GMP transition.
Preclinical studies underway
In vivo validation and toxicology programmes advancing through international research collaborations.
Partner with LSMedical.
We are building a safer future for diagnostic imaging through next-generation contrast technologies. For investor, clinical, research, or media inquiries, please reach out directly — messages route straight to the founding team.
Investor inquiries
Investment discussions, fundraising conversations, and strategic capital partnerships.
Partnerships
Pharmaceutical, imaging, and manufacturing partners exploring strategic collaboration.
Research collaborations
Hospital systems, imaging centres, research institutions, and clinical trial partners.
Media inquiries
Press, interviews, and editorial coverage of LSMedical and its work in next-generation contrast imaging.